Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Female Subjects
Launched by SOLVAY PHARMACEUTICALS · Aug 1, 2005
Trial Information
Current as of September 15, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Willing to sign informed consent before screening examinations are performed and before the study drug is administered
- • Females \> 18 years of age
- • Subjects with documented (60 second rhythm strip) symptomatic atrial fibrillation or flutter (duration \> 3 hours and \< 45 days) at the time of randomization
- • Subjects who are in no distress and hemodynamically stable (supine systolic blood pressure \> 90 mmHg and diastolic blood pressure \< 105 mmHg)
- Exclusion Criteria:
- • Pregnancy and lactation
- • Acute myocardial infarction and cerebrovascular accidents
- • Coronary syndromes and congestive heart failure (CHF) New York Heart Association (NYHA) IV
- • Life-threatening ventricular arrhythmias and electrocardiogram (ECG) abnormalities
- • Concurrent antiarrhythmic treatments
About Solvay Pharmaceuticals
Solvay Pharmaceuticals is a global biopharmaceutical company dedicated to improving patient health through innovative research and development. As a subsidiary of Solvay, a multinational chemical and advanced materials company, Solvay Pharmaceuticals focuses on delivering transformative therapies across various therapeutic areas, including central nervous system disorders, cardiovascular health, and women's health. Committed to scientific excellence and patient-centric solutions, the company collaborates with healthcare professionals and regulatory bodies to advance clinical trials and bring safe, effective medications to market, ultimately enhancing the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tullahoma, Tennessee, United States
Buenos Aires, Argentina
Buenos Aires, Argentina
Munro, Argentina
Tucuman, Argentina
Brno, Czech Republic
Jindrichuv Hradec, Czech Republic
Ostrava Poruba, Czech Republic
Plzen, Czech Republic
Prague, Czech Republic
Prague, Czech Republic
Prague, Czech Republic
Slany, Czech Republic
Usti Nad Orlici, Czech Republic
Belgrade, Former Serbia And Montenegro
Belgrade, Former Serbia And Montenegro
Belgrade, Former Serbia And Montenegro
Belgrade, Former Serbia And Montenegro
Belgrade, Former Serbia And Montenegro
Niska Banja, Former Serbia And Montenegro
Sremska Kamenica, Former Serbia And Montenegro
Bad Nauheim, Germany
Gottingen, Germany
Halle, Germany
Haifa, Israel
Jerusalem, Israel
Jerusalem, Israel
Jerusalem, Israel
Tel Aviv, Israel
Tel Aviv, Israel
Bydgoszcz, Poland
Bydgoszcz, Poland
Lodz, Poland
Lublin, Poland
Lublin, Poland
Medyczna, Poland
Szczecin, Poland
Warszawa, Poland
Warszawa, Poland
Warszawa, Poland
Warszawa, Poland
Wroclaw, Poland
Wroclaw, Poland
Brasov, Romania
Bucharest, Romania
Bucharest, Romania
Tg. Mures, Romania
Moscow, Russian Federation
Moscow, Russian Federation
Moscow, Russian Federation
Moscow, Russian Federation
Moscow, Russian Federation
Moscow, Russian Federation
Moscow, Russian Federation
Moscow, Russian Federation
Moscow, Russian Federation
Moscow, Russian Federation
St. Petersburg, Russian Federation
Banska Bystrica, Slovakia
Bratislava, Slovakia
Kosice, Slovakia
Lucenec, Slovakia
Nitra, Slovakia
Nove Zamky, Slovakia
Presov, Slovakia
Cape Town, South Africa
Cape Town, South Africa
Dnepropetrovsk, Ukraine
Dnepropetrovsk, Ukraine
Donetsk, Ukraine
Donetsk, Ukraine
Kharkiv, Ukraine
Kiev, Ukraine
Kiev, Ukraine
Kiev, Ukraine
Kiev, Ukraine
Lviv, Ukraine
Odessa, Ukraine
Zaporizhya, Ukraine
Zaporozhye, Ukraine
London, United Kingdom
Patients applied
Trial Officials
Global Clinical Director Solvay
Study Director
Solvay Pharmaceuticals
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials